The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Dr. Venkata Mattay
Project Title: Identifying molecular mechanisms underlying resilience to the neuropathological hallmarks of Late-onset Alzheimer�s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1603
Aim 1: Determine cognitive resilience relevant biological pathways significantly enriched with genes (whole transcript, exon and exon junctions) that are differentially expressed between ADPC and LOAD patients
Aim 2: Explore an epigenetic basis for resilience factors by identifying differentially methylated genetic regions (DMRs) at CpGs between LOAD and ADPC brains
Aim 3:
Aim 4:
Investigator: Jennifer Smith
Project Title: Optimization and Validation of a Cell-based Assay for Blood-Based Diagnosis of Alzheimer�s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1602
Aim 1: To test the performance of a recently developed indicator cell assay platform (iCAP) for blood-based diagnostics of AD. We propose to use 75 ADRC plasma samples to train and test iCAP-based classifiers to distinguish AD at pre-symptomatic and early stage of progression from normal controls.
Aim 2: To optimize the disease specificity of the AD iCAP. We propose to use 65 ADRC plasma samples to test and optimize the iCAP AD classifier�s ability to discriminate AD from other dementias such as lewy body dementia, frontotemporal dementia and vascular dementia.
Aim 3: To validate the final classifier with independent samples. We propose to use 125 ADRC plasma samples for blind independent testing of the classifiers. The final goal is a blood based iCAP for detection of presymptomatic and early AD with > 90% accuracy and specificity for AD over other dementias.
Aim 4: If only a fraction of the samples are available from ADRC, the project can be done using some samples from another source. In addition, as the aims are sequential, not all samples are required at once; we are willing to apply for approval in stages, contingent on meeting milestones for each aim.
Investigator: Richard Perrin, Anne Fagan, Hideaki Bujo
Project Title: Amendment to T1207 – Effects of APOE and AD on CSF sLR11
Date: December 21, 2021 at 5:02 pm
Request ID: T1207-B
Aim 1: Evaluate effect of APOE genotype on sLR11 levels in CSF
Aim 2: Evaluate effect of very early AD pathology on sLR11 levels in CSF
Aim 3:
Aim 4:
Investigator: Mike Nerenberg, MD
Project Title: Development of a Noninvasive Blood-Based Molecular Test for Monitoring Disease Progression in Alzheimer�s Disease.
Date: December 21, 2021 at 5:02 pm
Request ID: T1601
Aim 1: Refine gene selection and algorithms which better distinguish Alzheimer�s patients from age matched Normal cohorts.
Aim 2: Develop algorithms for circulating cell-free RNA by PCR assay to distinguish varying degrees of cognitive impairment and test the limits of detection in pre-clinical AD patients.
Aim 3:
Aim 4:
Investigator: David Holtzman
Project Title: Measurement of soluble tau in human brain
Date: December 21, 2021 at 5:02 pm
Request ID: T1517
Aim 1: measure tau levels in human brain from controls, Alzheimer’s disease, and CBD/PSP
Aim 2:
Aim 3:
Aim 4:
Investigator: Suzanne Schindler
Project Title: Correlates of longitudinal change in CSF biomarkers
Date: December 21, 2021 at 5:02 pm
Request ID: T1516
Aim 1: Characterization of intra-individual CSF biomarker changes
Aim 2: Correlation of CSF and imaging biomarkers of neurodegeneration
Aim 3: CSF biomarkers predict cognitive performance
Aim 4:
Investigator: Jarret Glasscock
Project Title: Circular RNAs as novel biomarkers of Alzheimer’s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1515
Aim 1: Identify Alzheimer�s specific circRNA in the CSF of patients with AD
Aim 2: Determine whether the levels of molecules in the circulating RNA panel are also elevated in a paired serum sample
Aim 3: Determine whether the circRNA panel can be used for early diagnosis of Alzheimer�s Disease
Aim 4:
Investigator: NJ Cairns
Project Title: Restoring progranulin in frontotemporal disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1514
Aim 1: To determine the efficacy of lead molecules in modulating progranulin in patient-derived cells
Aim 2:
Aim 3:
Aim 4:
Investigator: Randall J. Bateman
Project Title: Stable isotope labeling & quantitative mass spectrometry imaging of amyloid-beta (A�) plaque deposition in human Alzheimer�s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1513
Aim 1: Acquire in vivo stable isotope labeled images of A� plaques in human AD brain utilizing a validated NanoSIMS imaging protocol.
Aim 2: Develop a computational mathematical framework that accurately quantifies 13C6-leucine-labeled protein deposition into plaques
Aim 3:
Aim 4:
Investigator: John Crary
Project Title: Neuropathological studies of primary age-related tauopathy: the PART working group
Date: December 21, 2021 at 5:02 pm
Request ID: T1512
Aim 1: Aim 1. To validate the neuropathological criteria for PART and lay the groundwork for clinical and mechanistic studies that will elucidate disease burden, pathogenesis and progression.
Aim 2: Aim 2. To test the hypothesis that PART has a molecular signature consisting of AD-type tau pathology alongside non-amyloidogenic APP metabolites.
Aim 3: Aim 3. To test the hypothesis that PART has a genetic risk profile that overlaps with some aspects of AD genetics (e.g., MAPT haplotypes) but diverges with respect to others (e.g., APOE genotype).
Aim 4: